Search Results - adcc

3 Results

Sort By:

High Efficacy Vaccine and Microbicide Combination For Use Against HIV

Abstract: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant...

Published: 8/5/2024 | Inventor(s): Genoveffa Franchini, Marjorie Robert-Guroff, Daniel Appella, Sabrina Helmold Hait, Mohammed Rahman, Massimiliano Bissa, Ettore Appella, Lisa Marie Jenkins, Isabela Silva De Castro

Keywords(s): Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Vaccines

Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy

Abstract: Tumor necrosis factor receptor type 2 (TNFR2)-expressing regulatory T cells (Tregs), present in the tumor microenvironment, play an important role in tumor immune evasion. TNFR2 plays a crucial role in stimulating the activation and proliferation of Tregs, a major checkpoint of antitumor immune responses. In addition to its expression on Tregs,...

Published: 5/22/2024 | Inventor(s): Joost Oppenheim, Dimiter Dimitrov, De Yang, Xin Chen, Zhongyu Zhu

Keywords(s): ADCC, ANTIBODY, Antibody-dependent Cellular Cytotoxicity, CANCER, Immunotherapy, Oppenheim, TNFR2, Tregs, Tumor Necrosis Factor Receptor Type 2

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7

A highly efficient method to genetically modify natural killer (NK) cells to induce expression of high affinity CD16 (HA-CD16) through mRNA electroporation, to potentiate NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). ADCC is mediated by CD16+ NK cells following adoptive NK cell transfer, but most humans express CD16 which has a relatively...

Published: 7/25/2024 | Inventor(s): Mattias Carlsten, Richard Childs

Keywords(s): ADCC, antibodies, ANTIBODY, CBXXXX, CD16, ex vivo, Listed LPM Vathyam as of 4/15/2015, monoclonal, NK, NK Cells, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, TRANSFECTION, TUMORS, VCXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology